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Abstract： 
Early detection of small hepatocellular carcinoma (HCC) lesions can improve long-term patient 
survival. A systematic review and meta-analysis of the diagnostic performance of gadoxetic acid 
disodium-enhanced magnetic resonance imaging (Gd-EOB-DTPA-enhanced MRI) and 
multidetector computed tomography (MDCT) was performed in diagnosing small HCCs 
measuring up to 2 cm(≤2cm). Two investigators searched multiple databases for studies in which 
the performances of either Gd-EOB-DTPA-enhanced MRI or MDCT were reported with sufficient 
data to construct 2 × 2 contingency tables for diagnosing HCCs up to 2 cm on a per-lesion or 
per-patient level. Diagnostic performances were quantitatively pooled by a bivariate random-effect 
model with further meta-regression and subgroup analyses. Twenty-seven studies (fourteen on 
Gd-EOB-DTPA-enhanced MRI, nine on MDCT and four on both) were included, enrolling a total 
of 1735 patients on Gd-EOB-DTPA-enhanced MRI and 1781 patients on MDCT. 
Gd-EOB-DTPA-enhanced MRI demonstrated significantly higher overall sensitivity than did 
MDCT (0.96 vs 0.65, p＜0.01), without substantial loss of specificity (0.98 vs 0.94, p＞0.05). 
Area under the summary receiver operating characteristic curve was 0.9712 with 
Gd-EOB-DTPA-enhanced MRI and 0.8538 with MDCT. Regarding Gd-EOB-DTPA-enhanced 
MRI, sensitivity was significantly higher for studies from non-Asian countries than Asian 
countries(0.96 vs 0.93, p＜0.01), for retrospective studies than prospective studies(0.95 vs 0.91, p
＜0.01), and for those with Gd-EOB-DTPA injection rate≥1.5ml/s than that of＜1.5ml/s (0.97 vs 
0.90, p＜0.01). Conclusions: Gd-EOB-DTPA-enhanced MRI demonstrated higher sensitivity and 
overall diagnostic accuracy than MDCT, and thus should be the preferred imaging modality for 
diagnosing small HCCs measuring up to 2 cm. 
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Introduction 
Hepatocellular carcinoma (HCC) is the fifth most common cancer, the third leading cause of 
cancer-related mortality and the most common primary liver malignancies worldwide
1
. It occurs 
predominantly in patients with liver cirrhosis or chronic liver diseases
2
. Despite advances in 
treatment options including resection, liver transplantation, local-regional therapy and systematic 
chemotherapy for HCCs, long-term patient survival still calls for complete curative treatment of 
the early-stage HCCs, especially lesions smaller than 2 cm
2
. 
Currently, non-invasive imaging modalities play significant roles in the characterization and 
diagnosis of HCCs, with the diagnosis of HCC primarily based on multiphasic computed 
tomography (CT) or contrast-enhanced magnetic resonance imaging (CE-MRI) findings
3, 4
. 
However, small HCCs measuring up to 2 cm in diameter frequently present with atypical imaging 
features. Therefore, specified as they are, dynamic CT and conventional non-specific 
contrast-enhanced MRI may not be sensitive enough for small HCC nodules, with sensitivities 
ranging between 40-56%
5
 and 57-75%
6, 7
, respectively. Thus, accurate detection and 
characterization of early HCCs remain one of the most challenging areas in liver imaging.  
Fortunately, widespread applications of multidetector CT (MDCT) in recent years have led to 
improved HCC detection. Moreover, the introduction of a liver-specific hepatobiliary contrast 
agent-Gadoxetic acid disodium (Gd-EOB-DTPA), has further optimized the diagnostic 
performances of MRI for liver tumors. Gd-EOB-DTPA-enhanced MRI can provide both the 
hemodynamic information during early dynamic phases and better lesion characterization 
regarding hepatocyte presence and function in the hepatobiliary phase (HBP) in a single 
examination
8
. Several recent studies were dedicated to compare the diagnostic performances 
between MDCT and Gd-EOB-DTPA-enhanced MRI for small HCCs
9-12
, but their results may 
have been limited due to small study sample sizes. 
Therefore, the aim of our study was to conduct a meta-analysis evaluating and comparing the 
diagnostic performances of MDCT and Gd-EOB-DTPA-enhanced MRI for characterization of 
small HCCs measuring up to 2 cm. We also explored factors that may influence the diagnostic 
accuracies. 
 
Materials and Methods 
Search Strategy. Two independent investigators (Xijiao Liu and Hanyu Jiang ) conducted a 
systematic literature search in Pubmed, Web of Science, EMBASE, Cochrane Library, Springer 
Link, Science Direct, and Google Scholar to identify relevant articles published before February 
10, 2017 with the key words regarding “hepatocellular carcinoma”, “gadolinium ethoxybenzyl 
DTPA”, “magnetic resonance imaging”, and “multidetector computed tomography”. We restricted 
our research to articles concerning humans with an abstract in English. 
Study Selection. The two previously noted investigators independently reviewed the tittles, 
abstracts and full texts of the yielded original articles to determine whether they were eligible for 
further quantitative analyses. The inclusion criteria were as followed: (1) the article enrolled the 
diagnostic accuracy of MDCT or Gd-EOB-DTPA for HCC; (2) the article used reference standard 
based on: a. pathologic proof obtained after liver explant, resection and/or biopsy; b. evidence of 
conclusive imaging findings comprising arterial hypervascularity and venous or delayed phase 
washout 3, 4 and/or c. imaging follow-up of at least 6 months; (3) the article constituted an 
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original research instead of a review article, case report, letter, comment, guideline or a 
meta-analysis; (4) the study included original data addressing small HCC nodules measuring “up 
to 2 cm (≤ 2 cm)” , “less than 2 cm (＜2 cm)” or “1-2 cm”; (5) the total study population was 
more than 20; (6) sufficient data were available to calculate true-positive (TP), false-positive (FP), 
false-negative (FN) and true-negative (TN) values to construct a 2 × 2 contingency table. Articles 
were excluded if they were duplicate publications based on the same primary study. 
Disagreements between the two reviewers were resolved by consensus. Investigators of the 
original researches were approached to inquire more information for studies met all of the above 
criteria apart from sufficient data for the 2 ×2 table.  
Data Extraction and Quality Assessment. Two investigators (Hanyu Jiang and Jie Chen) 
reviewed the included studies and extracted the relevant details independently. Any discrepancy 
between the two investigators was resolved by consensus or consulting a senior radiologist (Bin 
Song) with more than 20 years of experience in hepatic disease diagnosis. 
To extract data of study characteristics, we recorded details regarding study authors, year of 
publication, country of origin, study design, blinding procedures, patient information, sizes of 
HCC evaluated, number of HCC lesions within measuring up to 2 cm, determination of results on 
a per-lesion or per-patient basis, reference standards, et al. We also recorded the image protocols 
of the following: MR and CT scanner, CT detector rows, CT contrast agents, Gd-EOB-DTPA 
dosage and injection rate, and inclusion of HBP or diffusion weighted imaging (DWI).  
TP, FN, TN, FP data for the performance of MDCT or Gd-EOB-DTPA-enhanced MRI in 
diagnosing up to 2 cm HCCs of each included study were extracted for the construction of the 2 × 
2 contingency table. If any diagnostic accuracy was reported for multiple observers, then the 
observer with the highest diagnostic accuracy was selected. Moreover, if any diagnostic accuracy 
was reported according to different imaging criteria, then, as is consistent with the current 
guidelines
3, 4
, the criteria which included both hyper enhancement or wash-in during the arterial 
phase and hypo enhancement or wash-out during the venous and/or delayed phase were required.  
The overall quality and likelihood of bias of the included studies were assessed according to 
Quality Assessment of Diagnostic Accuracy Studies (QUADAS)
 13
 by the two previously 
mentioned investigators (Hanyu Jiang and Jie Chen) independently. Notably, an interval between 
pathologic examination and the index test of 3 months and above or an overall imaging follow-up 
of 6 months or less were considered inappropriate. Besides, reference standards based on imaging 
follow-up of Gd-EOB-DTPA-enhanced MRI or MDCT findings were considered to have overlaps 
with and include knowledge of the index tests. Publication biases were evaluated with the Deeks 
funnel plots tests
14
. An inverted symmetrical funnel plot with P>0.05 was considered to indicate 
the absence of publication bias
14
. The publication bias was evaluated with Stata software (version 
12.0; StataCorp LP, College Station, TX). 
Statistical analysis. First, the sensitivity, specificity, and the corresponding 95% confidence 
intervals (CIs) for the diagnosis of small HCCs by MDCT and Gd-EOB-DTPA-enhanced MRI 
were calculated using a random-effects coefficient binary regression model
15
. We constructed 
summary receiver operating characteristic (SROC) curves and calculated the corresponding areas 
under the SROC curve (AUCs) of MDCT and Gd-EOB-DTPA-enhanced MRI to determine the 
diagnostic performances
16
. All estimations were performed with a multilevel mixed-effects 
logistic regression module which fitted the bivariate model in Meta-Disc software (version 1.4; 
Madrid, Spain). 
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A z test for unpaired groups was performed to compare the sensitivities and specificities of the 
two modalities with Microsoft Excel 11.0 (Microsoft, Redmond, WA), p＜0.05 was considered to 
indicate a significant difference. 
Heterogeneity Exploration and Subgroup Analysis. We evaluated heterogeneity between the 
included studies for each imaging modality with Meta-Disc software (version 1.4; Madrid, Spain). 
The heterogeneity was identified by the Q statistic of the Chi-square value test and the 
inconsistency index (I
2
), in which P<0.1 or I
2
>50 % indicated presence of heterogeneity
17
. A 
threshold effect is considered to exist in the presence of a positive correlation between the 
sensitivity and (1-specificity) of included studies. The absence of threshold effect was confirmed 
by not noticing the “shoulder-arm” shape in the SROC plane
16
. Upon detection of significant 
heterogeneity, single-factor meta-regression analyses and subgroup analyses were then performed 
to determine factors which contributed to the heterogeneity and their quantitative effects on the 
diagnostic results
18
. The subgroup analyses evaluated factors that could affect diagnostic 
performance and lead to heterogeneity. Sensitivity and specificity were calculated and compared 
for pairwise combinations of subgroups of studies defined by each of the recorded study 
characteristics with Stata software (version 12.0; StataCorp LP, College Station, TX). 
 
Results 
Study Selection. 2629 citations were initially identified upon removal of duplicates after the 
database search, of which 27 studies were in consistent with all the inclusion criteria and included 
in this meta-analysis
9-12, 19-41
 (Fig. 1). Among the included studies, 14 reported test performance of 
Gd-EOB-DTPA-enhanced MRI
19-32
, 9 of MDCT
33-41
, and 4 of both 
9-12
. Different studies reported 
by the same investigators (Di Martino, M
20, 35, 39
, and Park, MJ
23, 24
.) were included in our final 
meta-analysis; however, these studies were confirmed not to overlap according to different study 
periods
23, 24; 35, 39
, or because different imaging modalities were applied
20, 35
.  
Study Characteristics. Table 1 and Table 2 summarize the important characteristics of the 
included studies. A total of 1735 patients with 1482 HCC lesions measuring up to 2 cm underwent 
Gd-EOB-DTPA-enhanced MRI, while a total of 1781 patients with 793 HCC lesions underwent 
MDCT. Among these, a total of 276 patients underwent the two imaging modalities 
sequentially
9-12
. Most studies included patients with documented underlying liver cirrhosis or 
chronic liver disease. Assessment was performed on a per-patient basis in 2 studies
38, 41
 with 
MDCT and a per-lesion basis in the remaining studies. Imaging protocols of the included studies 
are demonstrated in Supplemental Table 1 and 2. 
Quality Assessment and Publication Biases. Quality assessment demonstrated that the qualities 
of the included studies were good. Fig. 2 shows a graphical display of QUADAS results 
concerning the proportion of included studies for each question. There were overall high scores for 
most questions from patient selection to explained withdrawals.  
The Deeks funnel plot showed that studies were distributed symmetrically on a scatter plot. The 
p values of the Deeks funnel plot asymmetry test for Gd-EOB-DTPA-enhanced MRI and MDCT 
were 0.52 and 0.18, respectively, demonstrating no evidence of notable publication bias. 
Diagnostic Performances. The overall pooled sensitivity of Gd-EOB-DTPA-enhanced MRI 
was significantly higher than that of MDCT (0.92 [95% CI: 0.90 to 0.93] vs 0.66 [95% CI: 0.63 to 
0.70], p＜0.01). The overall pooled specificity of Gd-EOB-DTPA-enhanced MRI was slightly 
lower than that of MDCT, but this difference was not statistically significant (0.89 [95% CI: 0.87 
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to 0.91] vs 0.91 [95% CI: 0.89 to 0.93], p＞0.05). Notably, four studies9-12 reported diagnostic 
performances of both Gd-EOB-DTPA-enhanced MRI and MDCT and thus allowed a head-to-head 
comparison between the two imaging modalities. Similarly, Gd-EOB-DTPA-enhanced MRI 
demonstrated significantly higher overall sensitivity than MDCT (0.96 [95% CI: 0.93 to 0.99] vs 
0.65 [95% CI: 0.57 to 0.73], p＜0.01), without substantial loss of specificity (0.94 [95% CI: 0.87 
to 1.00] vs 0.98 [95% CI: 0.95 to 1.00], p＞0.05). According to the SROC curve, the AUC was 
0.9712 with Gd-EOB-DTPA-enhanced MRI and 0.8538 with MDCT. Forest plots of sensitivities 
and specificities of different imaging modalities are shown in Fig. 3, while the SROC curves in 
Fig. 4. 
Heterogeneity Assessing and Meta-regression Analysis. Moderate to substantial heterogeneity 
was detected in our meta-analysis. I
2 
of sensitivity and specificity were 82.0% and 88.7% for 
Gd-EOB-DTPA-enhanced MRI, while 75.3% and 69.9% for MDCT, respectively. Threshold 
effects of Gd-EOB-DTPA-enhanced MRI and MDCT were eliminated through the SROC planes, 
which showed no “shoulder-arm” shapes. Neither single-factor nor multi-factor meta-regression 
analyses showed any study characteristic that contributed statistically significantly to 
heterogeneity for Gd-EOB-DTPA-enhanced MRI or MDCT. 
Subgroup Analyses. As considerable heterogeneity was revealed, we performed subgroup 
analyses between different study characteristics in Gd-EOB-DTPA-enhanced MRI to evaluate 
their quantitative effects on heterogeneity (Table. 3). Sensitivities were significantly higher for 
studies originated from non-Asian countries compared with those originated from Asia (0.96 vs 
0.93, p＜0.01), those with a retrospective design compared with prospective design (0.95 vs 0.91, 
p＜0.01), and those performed with Gd-EOB-DTPA injection rate ≥1.5ml/s compared with ＜
1.5ml/s (0.97 vs 0.90, p＜0.01), and those performed with sequential Gd-EOB-DTPA-enhanced 
MRI compared with those not (0.96 vs 0.92, p=0.01). Subgroup analysis was not performed for 
MDCT due to insufficient studies number (fewer than 4) in each subgroup to perform 
data-syntheses analysis. 
 
Discussions 
Results of our study showed that Gd-EOB-DTPA-enhanced MRI demonstrated higher 
sensitivity and overall diagnostic accuracy than MDCT, with AUCs of 0.9712 and 0.8538 
respectively. A diagnostic tool is generally defined as perfect if the AUC is 1, excellent if the AUC 
is greater than 0.9, and good if the AUC is greater than 0.8
42
. According to this, 
Gd-EOB-DTPA-enhanced MRI had an excellent diagnostic accuracy, while MDCT good for 
diagnosing small HCCs. 
Currently, all major clinical practice guidelines endorse multiphasic CT and MR imaging with 
extracellular contrast agents as the first-line modalities for diagnosis and staging of HCC
3, 4
. 
However, on the basis of our study results, Gd-EOB-DTPA-enhanced MRI should be the preferred 
modality for evaluating small HCCs because it provided better lesion detection ability and higher 
overall diagnostic accuracy, without significant loss of specificity. 
During hepatocarcinogenesis, most HCCs evolve from histologically abnormal precursor 
lesions and undergo a multistep from cirrhotic nodules, low-grade dysplastic nodules (LGDNs), 
high-grade dysplastic nodules (HGDNs), early HCCs to progressed HCCs
43
. During these steps, 
the intranodular arterial supply decreases initially and increases afterwards
43
. Therefore, despite 
that progressed HCCs usually show typical arterial hypervascularity compared with background 
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liver, earlier nodules typically do not. Thus, MDCT and extracellular agents-enhanced MRI 
demonstrate limited potential in identifying and differentiating early HCCs from the benign liver 
nodules
5-7 
based on typical vascular enhancement patterns. Gd-EOB-DTPA, on the other hand, is 
taken predominantly by hepatocytes via the organic anion transporter polypeptides OATP1B1/B3 
and excreted via the multidrug resistance-associated proteins MRP2
8
. In early HCCs, 
OATP1B1/B3 expression is usually reduced or absent relative to that of the liver parenchyma, 
while MRP2 expression is usually elevated
8
. Thus, the accumulation of Gd-EOB-DTPA often 
diminishes progressively from cirrhotic nodules to progressed HCCs compared to the background 
liver
8
. In HBP, most HCCs appear as low signal intensity foci against the enhancing high signal 
parenchyma in the HBP. This nature enables Gd-EOB-DTPA-enhanced MRI to be highly sensitive 
for the diagnosis of early HCC lesions and for their differentiation from DNs and vascular 
psedoleisions, in which the delayed hypointensity in HBP is often absent
10
. 
Our research revealed that Gd-EOB-DTPA-enhanced MRI demonstrated a significantly higher 
sensitivity and overall accuracy for small HCCs than multiphasic MDCT without substantial loss 
of specificity, which was in accordance with several previous comparative studies. Onishi et al
44
 
retrospectively analyzed 73 hypervascular HCC lesions from 31 suspected HCC patients, and 
found that for the subgroup with lesions less than 1 cm the combined dynamic and HBP MR 
images with Gd-EOB-DTPA demonstrated a significantly higher sensitivity than MDCT (48% vs 
11%, p＜0.001); while with lesions 1–2 cm the mean sensitivity for combined MRI was higher 
than multiphasic MDCT (75% vs 58%) as well, although the difference was not statistically 
significant. Likewise, Tsurusaki et al
45
 included fifty-four patients with 83 histopathologically 
confirmed HCCs in their study. They reported that the combined interpretation of the dynamic and 
HBP of Gd-EOB-DTPA-enhanced MRI showed statistically higher sensitivity for lesion detection 
than multiphasic MDCT images in the nineteen ≤1cm lesions (58% vs 28%, p=0.0037) and 
thirty-two 1-2 cm lesions (84% vs 73%, p=0.015). Böttcher et al
46
 also retrospectively analyzed 29 
patients with 130 liver lesions and revealed that for HCC lesions＜20 mm, 
Gd-EOB-DTPA-enhanced- MRI was able to detect more lesions, with 10.3% and 23.7% of lesions 
missed by MRI and MDCT respectively, and yielded a significantly higher diagnostic accuracy 
than MDCT (88.9% vs 67.6%, p＜0.01). 
A possible explanation is that, as discussed above, functional changes of OATP1B1/B3 and 
MRP2 usually happen ahead of neovascularization and are more specific hallmarks for early 
HCCs during hepatocarcinogenesis. Therefore, since diagnosis of HCC with MDCT is 
predominantly dependent on the typical vascular patterns, Gd-EOB-DTPA-enhanced MRI is able 
to identify the minute HCC lesions at an earlier stage.  
Nevertheless, this finding can also be the result that, more retrospective studies were included 
on Gd-EOB-DTPA-enhanced MRI than did MDCT (13/18 retrospective studies of 
Gd-EOB-DTPA-enhanced MRI vs 4/13 retrospective studies of MDCT) in our study. As 
retrospective studies are more likely to cause a bias toward increased diagnostic sensitivity
47
, this 
may have resulted in overestimated sensitivity of Gd-EOB-DTPA-enhanced MRI for diagnosing 
small HCCs. Besides, it should be recognized that Gd-EOB-DTPA-enhanced MRI is more 
expensive, less available, less rapid, less robust, more sensitive to motion artifact and require more 
expertise to perform and interpret images compared with MDCT. Therefore, 
Gd-EOB-DTPA-enhanced MRI may not be recommended in communities or less-specialized 
medical centers, and that more researches are needed to optimize the timing and image quality of 
Page 8 of 28
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
9 
Gd-EOB-DTPA-enhanced MRI for characterizing small HCCs precisely. 
The subgroup analysis revealed that Gd-EOB-DTPA injection rate ≥1.5ml/s was associated 
significantly with increased sensitivity (0.97 vs 0.90, p＜0.01) for small HCCs without loss of 
specificity (0.92 vs 0.95, p=0.34). However, this was not in line with previous studies. Currently, 
some believe that lower injection rates of Gd-EOB-DTPA are more likely to lead to higher 
relaxivity that can help avoid saturation effect and thus result in increased probability of obtaining 
optimal hepatic arterial phase timing with the help of better arterial enhancement and decreased 
patients’ discomfort
48
 Chung et al
48
 revealed that, with their study performed on a 3.0-T MR 
system, gadoxetic acid injection rates of 1ml/s rate and 2ml/s ensured comparable image quality 
and detection of focal hypervascular hepatic lesions, but nearly half of their included HCC lesions 
were＞2cm (11/24 of 1ml/s and 10/21 of 2ml/s). On the other hand, another study showed that 
1ml/s injection rate achieved greater aorta enhancement and aortic perfusion parameters than 2 
ml/s on a 1.5-T MR system
49
. However, the included patients were not restricted to have HCCs, 
and diagnostic performances were not evaluated in their study neither. The difference between our 
result and these studies may have been due to different lesion size ranges, experience of 
radiologists and image quality among medical centers. Therefore, further prospective studies in 
consecutive patients are needed to refine and validate the best injection rate of Gd-EOB-DTPA for 
diagnosing small HCCs. 
The subgroup analysis also showed that, for Gd-EOB-DTPA-enhanced MRI, retrospective 
studies demonstrated higher sensitivity than did prospective studies (0.95 vs 0.91, p＜0.01), of 
which the possible explanation has been discussed above.  
Another interesting result of the subgroup analysis was that studies originated from non-Asian 
(Italy and USA) countries demonstrated significantly higher sensitivity than did studies from 
Asian countries (0.96 vs 0.93, p=0.01). This could be explained by earlier introduction of 
Gd-EOB-DTPA-enhanced MRI in Italy and USA, resulting in increased experience of radiologists 
in diagnosing small HCCs. However, this finding was not in keep with previous studies. Kierans 
et al
6
 conducted a meta-analysis on the diagnostic performance of MRI for ≤2cm HCCs with 22 
studies, their result revealed that Asian studies yielded higher sensitivity than other studies, but 
this difference was eliminated after adjusting for the effect of inclusion of HBP. Nevertheless, 
their result was based on all MRI modalities without excluding contrast agents except for 
Gd-EOB-DTPA. Besides, while our research involved 18 studies considering Gd-EOB-DTPA, 
Kierans et al only included 7. 
Our meta-analysis has several limitations. First, we included limited number of prospective 
studies in our research. This may have led to a major methodologic limitation of collecting and 
pooling many suboptimal retrospective data, resulting in overestimated diagnostic sensitivity. 
Second, only studies published in English were included in our meta-analysis, possibly to have led 
to the “Tower of Babel” bias in which the non-English speaking authors tend to only submit 
studies with positive results to international journals published in English
50
.  
Third, substantial heterogeneity was detected for both Gd-EOB-DTPA-enhanced MRI and 
MDCT, which may have affected the general applicability of the summary estimates. Therefore, 
we implied the summary ROC model and the random effects model to overcome the heterogeneity 
of our data. With relatively narrow 95% CI, we believe that our results should be valuable in 
clinical practices. Moreover, single-factor meta-regression analyses and subgroup analyses were 
conducted to determine factors which contributed to the heterogeneity and their quantitative 
Page 9 of 28
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
10 
effects on the diagnostic results. However, several sources of heterogeneity including patient 
disease severity, radiologists’ experience difference and pathologists’ criteria variation, may not 
have been well explored in our meta-analysis, so the heterogeneity remained a point of concern. 
Fourth, we didn’t conduct a subgroup analysis for MDCT due to limited number of studies for 
each study characteristic. 
Finally, only four included studies
9-12
 evaluating the diagnostic performances of both 
Gd-EOB-DTPA and MDCT for small HCCs were available and included. In these studies, a total 
of 276 patients underwent the two imaging modalities sequentially, allowing the most reliable 
head-to-head comparison. However, the quality of quantitative analysis might have been affected 
by the limited number of studies. In order to deal with this issue, an unpaired comparison 
involving all of the included studies was established. As revealed by the pooled results, 
Gd-EOB-DTPA-enhanced MRI demonstrated significantly higher sensitivities than MDCT in 
either head-to-head or unpaired comparisons, without substantial loss of specificities. These 
findings indicated that our unpaired data were reliable. But this methodology may have introduced 
biases which couldn't be resolved yet. Therefore, more large-scale, prospective studies assessing 
the test performances of both Gd-EOB-DTPA and MDCT based on same cohorts are encouraged.  
In conclusion, Gd-EOB-DTPA-enhanced MRI, compared with multiphasic MDCT, 
demonstrated better sensitivity and overall accuracy without loss of specificity, especially with 
higher injection rate of ≥1.5ml/s. Therefore, Gd-EOB-DTPA-enhanced MRI should be the 
preferred imaging modality for the diagnosis of small HCCs measuring up to 2cm.  
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Table 1. Characteristics of the included 18 MRI studies 
 
N
o 
Stud
y 
Year 
publ
ishe
d 
Nati
on 
T
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F
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T
N 
F
N 
No. 
of  
Patie
nts 
No. of 
HCC 
Lesions
† 
HCC 
Size  
Stud
y 
Desi
gn 
Enrollment patients Reference Standard 
1 Anh19 2010 Korea 25 0 3 1 59 26 1-2cm Retro 
consecutive cirrhosis 
patients,12mo(4/07-3/08) 
Surgical findings, biopsy, 
lipiodol uptake after TACE, or 
imaging follow-up 
2 
Di 
Martino 
20
 
2010 Italy 47 2 18 8 58 55 ≤2cm pro 
consecutive cirrhosis 
patients,21mo(2/07-10/08) 
Pathologic proof, conclusive 
imaging result, or imaging 
follow-up  
3 Sun9 2010 Korea 31 2 25 2 69 44 ≤2cm Retro 
consecutive cirrhosis 
patients,10mo(5/08-2/09) 
Biopsy, resection, angiography, 
lipiodol uptake after TACE, or 
serum a-fetoprotein level 
4 
Golfieri 
21
 
2011 Italy 
17
2 
2 40 1 127 173 ≤2cm Pro 
consecutive cirrhosis 
patients,18mo(5/08-10/09) 
Surgical findings, biopsy, 
lipiodol uptake after TACE, or 
imaging follow-up 
5 Kim22 2011 Korea 50 0 3 4 40 54 ≤2cm Pro 
consecutive 
patients,11mo(8/09-6/10) 
Surgical findings, characteristic 
imaging results, lipiodol uptake 
after TACE, or imaging 
follow-up 
6 Sano10 2011 Japan 88 6 155 3 64 96 ≤2cm Retro 
consecutive 
patients,23mo(1/08-11/09) 
Surgical findings and 
Pathologic proof 
7 Park23 2012 Korea 
16
6 
3 141 13 130 179 ≤2cm Retro 
consecutive 
patients,15mo(5/09-7/10) 
Surgical findings and 
Pathologic proof, biopsy 
8 Park24 2013 Korea 
10
1 
3 20 1 108 102 ≤2cm Retro 
consecutive cirrhosis 
patients,17mo(4/10-8/11) 
Surgical findings and 
Pathologic proof, biopsy 
9 
Granito
11
 
2013 Italy 24 3 5 0 33 24 1-2cm Pro 
consecutive cirrhosis 
patients,59mo(12/08-10/13
) 
Biopsy and imaging follow up 
10 
Hwang
25
 
2014 Korea 47 3 43 21 63 68 ≤2cm Retro 
consecutive 
patients,67mo(4/08-10/13) 
Surgical findings and 
Pathologic proof 
11 Zhao26 2014 China 33 4 16 1 33 34 ≤2cm Retro 
consecutive cirrhosis 
patients,17mo(8/11-12/12) 
Pathologic proof, conclusive 
imaging result, or lipiodol 
uptake after TACE  
12 
Faletti
2
7
 
2015 Italy 27 0 10 2 28 28 ＜2cm Retro 
consecutive cirrhosis 
patients,34mo(1/10-10/12) 
Surgical findings and 
Pathologic proof 
13 Joo28 2015 Korea 78 6 64 19 288 97 ＜2cm Retro 
consecutive 
patients,9mo(9/12-5/13) 
Pathologic proof, conclusive 
imaging result, or imaging 
follow-up 
14 Kwon29 2015 Korea 20 9 52 21 230 222 ≤2cm Retro consecutive cirrhosis Surgical findings and 
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1 patients,20mo(11/09-6/11) Pathologic proof, biopsy 
15 Chen12 2016 Japan 41 1 22 2 139 43 ＜2cm Retro 
consecutive 
patients,70mo(1/08-10/13) 
Surgical findings and 
Pathologic proof, biopsy 
16 
Pahad
e
30
 
2016 
Americ
an 
9 11 12 1 30 12 ≤2cm Retro 
consecutive 
patients,30mo(1/10-6/12) 
Surgical findings and 
Pathologic proof, biopsy 
17 Yim 31 2016 Korea 31 0 81 3 38 131 ≤2cm Retro 
consecutive cirrhosis 
patients,36mo(1/08-12/10) 
Pathologic proof, conclusive 
imaging result, or imaging 
follow-up 
18 Choi 32 2016 Korea 78 21 69 16 198 94 ≤2cm Pro 
consecutive cirrhosis 
patients,12mo(1/11-12/11) 
Pathologic proof, marginal 
recurrence after TACE or RFA, 
or imaging follow-up 
TP, true-positive; FP, false-positive; TN, true-negative;FN, false-negative; †, the number of HCC lesions of the correspongding sizes; TACE 
transcatheter arterial chemoembolization; RFA radiofrequency ablation. 
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Table 2. Characteristics of the included 13 MDCT studies 
No Study 
Year 
publ
ishe
d 
Nati
on 
T
P 
F
P 
T
N 
F
N 
No. 
of  
Patie
nts 
No. 
of 
HCC 
Lesio
ns† 
HCC 
Size  
Stud
y 
Desi
gn 
Enrollment patients Reference Standard 
1 Bolondi33 2005 Italy 9 1 11 10 59 29 1-2cm Pro 
consecutive cirrhosis 
patients,18mo(10/02-3/04) 
Biopsy,conclusive imaging result, 
or imaging follow-up  
2 Ichikawa34 2005 Japan 36 38 227 5 60 76 ＜2cm Pro 
consecutive cirrhosis 
patients,26mo(8/00-9/02) 
Biopsy,conclusive imaging result, 
or imaging follow-up  
3 
Di 
Martino
35
 
2010 Italy 33 3 17 22 58 55 ≤2cm Pro 
consecutive cirrhosis 
patients,21mo(2/07-10/08) 
Pathologic proof,conclusive 
imaging result, or imaging follow-up 
4 
Sangiovan
ni
36
 
2010 Italy 15 0 21 19 64 34 1-2cm Pro 
consecutive cirrhosis 
patients 
Biopsy 
5 Sun9 2010 Korea 18 1 26 15 69 44 ≤2cm Retro 
consecutive cirrhosis 
patients,9mo(5/08-1/09) 
Biopsy, resection, angiography, 
lipiodol uptake after TACE, or 
serum a-fetoprotein level 
6 Khalili37 2011 
Canad
a 
18 6 61 16 84 101 1-2cm Pro 
consecutive cirrhosis 
patients 
Pathologic proof, or imaging 
follow-up  
7 Sano10 2011 Japan 62 4 157 29 64 96 ≤2cm Retro 
consecutive 
patients,23mo(1/08-11/09) 
Resection and Pathologic proof 
8 Serste38 2012 France 35 5 22 12 74 47 1-2cm Pro 
consecutive 
patients,60mo(1/05-12/10) 
Biopsy 
9 
Di 
Martino
39
 
2013 Italy 54 5 42 29 140 105 ≤2cm Pro 
consecutive cirrhosis 
patients,43mo(1/07-7/10) 
Pathologic proof, or imaging 
follow-up  
10 Granito11 2013 Italy 12 0 8 12 33 24 1-2cm Pro 
consecutive cirrhosis 
patients,38mo(12/08-1/11) 
Biopsy and imaging follow up 
11 Jang40 2013 Korea 21 3 71 15 96 36 1-2cm pro 
consecutive 
patients,32mo(1/06-8/08) 
Pathologic proof, recurrence or 
metastasis after local ablation 
therapy, or imaging follow-up 
12 Chen12 2016 Japan 32 0 23 11 139 43 ＜2cm Retro 
consecutive 
patients,70mo(1/08-10/13) 
Surgical findings and Pathologic 
proof 
and biopsy 
13 Lin41 2016 China 84 8 20 19 841 103 1-2cm Retro 
consecutive 
patients,58mo(1/06-10/10) 
Surgical findings and Pathologic 
proof 
TP, true-positive; FP, false-positive; TN, true-negative;FN, false-negative; †, the number of HCC lesions of the correspongding sizes; TACE transcatheter 
arterial chemoembolization. 
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Table 3. Subgroup analysis 
Subgroup 
No. of 
Studies 
Pooled Sensitivity 
(95% CI) 
P 
value 
Pooled Specificity 
(95% CI) 
P 
value 
Country 
Asian 13 0.93(0.89-0.97) 
＜0.01 
0.94(0.90-0.98) 
＞0.99 
Others 5 0.96(0.92-0.99) 0.85(0.72-0.99) 
Design 
Prospective 5 0.91(0.83-0.98) 
＜0.01 
0.88(0.77-0.99) 
0.05 
Retrospective 13 0.95(0.91-0.98) 0.94(0.89-0.98) 
Cirrhosis 
With cirrhosis 12 0.94(0.90-0.98) 
0.08 
0.93(0.89-0.98) 
0.54 
Without cirrhosis 6 0.93(0.87-0.99) 0.89(0.79-0.99) 
Field Strength 
1.5T 8 0.93(0.88-0.99) 
0.06 
0.92(0.86-0.99) 
0.18 
3.0T 6 0.95(0.91-0.99) 0.94(0.89-0.99) 
Gd-EOB-DTPA injection rate 
＜1.5ml/s 10 0.90(0.85-0.95) 
＜0.01 
0.95(0.91-0.99) 
0.34 
≥1.5ml/s 6 0.97(0.95-0.99) 0.92(0.85-0.99) 
HBP 
With HBP 18 0.94(0.91-0.97) 
0.35 
0.91(0.86-0.96) 
0.15 
Without HBP 4 0.88(0.78-0.98) 0.96(0.90-0.99) 
Lesion Diameter 
＜2cm 18 0.94(0.91-0.97) 
0.89 
0.92(0.88-0.97) 
0.19 
＜1cm 6 0.83(0.70-0.97) 0.93(0.86-0.99) 
Sequential test 
Yes 4 0.96(0.93-0.99) 
0.01 
0.94(0.87-1.00) 
0.36 
No 14 0.92(0.88-0.96) 0.92(0.88-0.96) 
Gd-EOB-DTPA, gadoxetic acid disodium; HBP, hepato-biliary phase. 
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Fig.1 Flowchart illustrating the selection of studies  
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Fig.2 Methodological quality of the 31 included studies  
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Fig.3 Forest plots of sensitivities and specficities of gadoxetic acid disodium-enhanced magnetic resonance 
imaging(3a,3b) and multidetector computed tomography(3c,3d) for small HCC  
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Fig.4 Summary receiver operating characteristic (SROC) curves of gadoxetic acid disodium-enhanced 
magnetic resonance imaging (4a) and multidetector computed tomography (4b) for small HCCs measuring 
up to 2 cm(≤2cm)  
 
169x70mm (300 x 300 DPI)  
 
 
Page 21 of 28
John Wiley & Sons, Inc.
Liver Transplantation
This article is protected by copyright. All rights reserved.
